Basic Searches
Searches without any special characters (listed below) will return items that contain the exact value(s) entered in the search field. This means that searching for "ASPIRIN CALCIUM" won't return any items that have "ASPIRIN GLYCINE CALCIUM" because the search term doesn't match exactly.
Boolean Operators
OR - searches with terms separated by " OR " will return items that contain any of the terms in the search.
Example: "ASPIRIN" OR "CALCIUM" will return items that have strings like "ASPIRIN GLYCINE" and "GLYCINE CALCIUM" because they contain at least one of the terms in the search.

AND - searches with terms separated by " AND " will return items that contain all the terms in the search.
Example: "ASPIRIN" AND "CALCIUM" won't return items that have strings "ASPIRIN GLYCINE" and "GLYCINE CALCIUM" because neither contain both terms, but it will return "ASPIRIN GLYCINE CALCIUM" because it contains both search terms.
version 2.7.1
Substance Class Protein
Protein Type ENZYME
Protein Sub Type CYTOCHROME P450
Sequence Origin HUMAN
Sequence Type COMPLETE
Record UNII
0UY97CSG1T
Record Status Validated
Record Version
Show Definitional References Hide Definitional References
Download
Name Type Language Details Access References
CYTOCHROME P450 2B6
Common Name
English  
HUMAN CYTOCHROME P450 2B6
Common Name
English  
CYTOCHROME P 450 2B6
Common Name
English  
CYP2B6
Common Name
English  
1,4-CINEOLE 2-EXO-MONOOXYGENASE
Common Name
English  
Code System Code Type Description Access References
CAS
330207-11-9
Created by admin on Wed Aug 04 21:57:02 EDT 2021 , Edited by admin on Wed Aug 04 21:57:02 EDT 2021
PRIMARY
FDA UNII
0UY97CSG1T
Created by admin on Wed Aug 04 21:57:02 EDT 2021 , Edited by admin on Wed Aug 04 21:57:02 EDT 2021
PRIMARY
UNIPROT
P20813
Created by admin on Wed Aug 04 21:57:02 EDT 2021 , Edited by admin on Wed Aug 04 21:57:02 EDT 2021
PRIMARY
Related Record Type Details Access References
INHIBITOR -> TARGET
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:57:09 EDT 2021 , Edited by admin on Wed Aug 04 21:57:09 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 21:57:02 EDT 2021 , Edited by admin on Wed Aug 04 21:57:02 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:06 EDT 2021 , Edited by admin on Wed Aug 04 21:57:06 EDT 2021
INDUCER -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:07 EDT 2021 , Edited by admin on Wed Aug 04 21:57:07 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:07 EDT 2021 , Edited by admin on Wed Aug 04 21:57:07 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:06 EDT 2021 , Edited by admin on Wed Aug 04 21:57:06 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
Screening of potential CYP2B6 inhibitions illustrates that CYP2B6 activity was extensively inhibited by all tested organophosphate pesticides. Malathion and phenthoate resulted in 91% inhibition.
Created by admin on Wed Aug 04 21:57:02 EDT 2021 , Edited by admin on Wed Aug 04 21:57:02 EDT 2021
INDUCER -> METABOLIC ENZYME
Mediator Substance Details
none
Rifamycin is an inducer of CYP3A4 and CYP2B6 but not CYP1A2 in vitro, however, based on systemic concentrations of rifamycin observed after administration of the recommended dose, clinically relevant induction of these enzymes in vivo is unlikely.
Created by admin on Wed Aug 04 21:57:09 EDT 2021 , Edited by admin on Wed Aug 04 21:57:09 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:08 EDT 2021 , Edited by admin on Wed Aug 04 21:57:08 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:10 EDT 2021 , Edited by admin on Wed Aug 04 21:57:10 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
Ki
Created by admin on Wed Aug 04 21:57:16 EDT 2021 , Edited by admin on Wed Aug 04 21:57:16 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:10 EDT 2021 , Edited by admin on Wed Aug 04 21:57:10 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
IC50
Created by admin on Wed Aug 04 21:57:07 EDT 2021 , Edited by admin on Wed Aug 04 21:57:07 EDT 2021
NON-INHIBITOR -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:15 EDT 2021 , Edited by admin on Wed Aug 04 21:57:15 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:57:05 EDT 2021 , Edited by admin on Wed Aug 04 21:57:05 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:04 EDT 2021 , Edited by admin on Wed Aug 04 21:57:04 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:03 EDT 2021 , Edited by admin on Wed Aug 04 21:57:03 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
SELECTIVE
Created by admin on Wed Aug 04 21:57:06 EDT 2021 , Edited by admin on Wed Aug 04 21:57:06 EDT 2021
INDUCER -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:02 EDT 2021 , Edited by admin on Wed Aug 04 21:57:02 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:06 EDT 2021 , Edited by admin on Wed Aug 04 21:57:06 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:08 EDT 2021 , Edited by admin on Wed Aug 04 21:57:08 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 21:57:03 EDT 2021 , Edited by admin on Wed Aug 04 21:57:03 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
WEAK
Created by admin on Wed Aug 04 21:57:08 EDT 2021 , Edited by admin on Wed Aug 04 21:57:08 EDT 2021
INDUCER -> METABOLIC ENZYME
Mediator Substance Details
none
Zanubrutinib induces CYP2B6 in vitro.
Created by admin on Wed Aug 04 21:57:07 EDT 2021 , Edited by admin on Wed Aug 04 21:57:07 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:11 EDT 2021 , Edited by admin on Wed Aug 04 21:57:11 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:57:07 EDT 2021 , Edited by admin on Wed Aug 04 21:57:07 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
IC50
Created by admin on Wed Aug 04 21:57:07 EDT 2021 , Edited by admin on Wed Aug 04 21:57:07 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:02 EDT 2021 , Edited by admin on Wed Aug 04 21:57:02 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:02 EDT 2021 , Edited by admin on Wed Aug 04 21:57:02 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 21:57:06 EDT 2021 , Edited by admin on Wed Aug 04 21:57:06 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
3.2% conversion to M1
Created by admin on Wed Aug 04 21:57:06 EDT 2021 , Edited by admin on Wed Aug 04 21:57:06 EDT 2021
INDUCER -> METABOLIC ENZYME
Mediator Substance Details
none
tafamidis induced CYP2B6 in vitro with an EC50 of 25 ?M.
EC50
Created by admin on Wed Aug 04 21:57:04 EDT 2021 , Edited by admin on Wed Aug 04 21:57:04 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 21:57:07 EDT 2021 , Edited by admin on Wed Aug 04 21:57:07 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:06 EDT 2021 , Edited by admin on Wed Aug 04 21:57:06 EDT 2021
INDUCER -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:12 EDT 2021 , Edited by admin on Wed Aug 04 21:57:12 EDT 2021
NON-SUBSTRATE -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:10 EDT 2021 , Edited by admin on Wed Aug 04 21:57:10 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:03 EDT 2021 , Edited by admin on Wed Aug 04 21:57:03 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:08 EDT 2021 , Edited by admin on Wed Aug 04 21:57:08 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
Screening of potential CYP2B6 inhibitions illustrates that CYP2B6 activity was extensively inhibited by all tested organophosphate pesticides. Phenthoate resulted in 91% inhibition.
Created by admin on Wed Aug 04 21:57:02 EDT 2021 , Edited by admin on Wed Aug 04 21:57:02 EDT 2021
INDUCER -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:03 EDT 2021 , Edited by admin on Wed Aug 04 21:57:03 EDT 2021
NON-INDUCER -> METABOLIC ENZYME
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:16 EDT 2021 , Edited by admin on Wed Aug 04 21:57:16 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
IC50
Created by admin on Wed Aug 04 21:57:08 EDT 2021 , Edited by admin on Wed Aug 04 21:57:08 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:57:07 EDT 2021 , Edited by admin on Wed Aug 04 21:57:07 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:10 EDT 2021 , Edited by admin on Wed Aug 04 21:57:10 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
Rifamycin is an inhibitor of CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A4/5 in vitro, however, based on systemic concentrations of rifamycin observed after administration of the recommended dose clinically relevant inhibition of these enzymes in vivo is unlikely.
Created by admin on Wed Aug 04 21:57:09 EDT 2021 , Edited by admin on Wed Aug 04 21:57:09 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:13 EDT 2021 , Edited by admin on Wed Aug 04 21:57:13 EDT 2021
PARENT->INNOVATOR
Mediator Substance Details
none
Screening of potential CYP2B6 inhibitions illustrates that CYP2B6 activity was extensively inhibited by all tested organophosphate pesticides. Inhibition percentages were 100% with profenofos.
Created by admin on Wed Aug 04 21:57:02 EDT 2021 , Edited by admin on Wed Aug 04 21:57:02 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:08 EDT 2021 , Edited by admin on Wed Aug 04 21:57:08 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:05 EDT 2021 , Edited by admin on Wed Aug 04 21:57:05 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
CYP2B6 preferentially metabolized (S)-methadone,
Created by admin on Wed Aug 04 21:57:08 EDT 2021 , Edited by admin on Wed Aug 04 21:57:08 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:07 EDT 2021 , Edited by admin on Wed Aug 04 21:57:07 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:03 EDT 2021 , Edited by admin on Wed Aug 04 21:57:03 EDT 2021
INDUCER -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:14 EDT 2021 , Edited by admin on Wed Aug 04 21:57:14 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:57:08 EDT 2021 , Edited by admin on Wed Aug 04 21:57:08 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:13 EDT 2021 , Edited by admin on Wed Aug 04 21:57:13 EDT 2021
INDUCER -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:03 EDT 2021 , Edited by admin on Wed Aug 04 21:57:03 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:10 EDT 2021 , Edited by admin on Wed Aug 04 21:57:10 EDT 2021
TISSUE EXPRESSION -> PARENT
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:10 EDT 2021 , Edited by admin on Wed Aug 04 21:57:10 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 21:57:05 EDT 2021 , Edited by admin on Wed Aug 04 21:57:05 EDT 2021
NON-SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:07 EDT 2021 , Edited by admin on Wed Aug 04 21:57:07 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:03 EDT 2021 , Edited by admin on Wed Aug 04 21:57:03 EDT 2021
TISSUE EXPRESSION -> PARENT
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:10 EDT 2021 , Edited by admin on Wed Aug 04 21:57:10 EDT 2021
INDUCER -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:10 EDT 2021 , Edited by admin on Wed Aug 04 21:57:10 EDT 2021
NON-SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:15 EDT 2021 , Edited by admin on Wed Aug 04 21:57:15 EDT 2021
INDUCER -> METABOLIC ENZYME
none
Mediator Substance Details
none
ACTIVATOR
Created by admin on Wed Aug 04 21:57:09 EDT 2021 , Edited by admin on Wed Aug 04 21:57:09 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
In vitro metabolism studies involving recombinant enzymes indicated that CYP3A4, CYP1A1, CYP3A5, CYP2C9, CYP2C19 and CYP2B6 were responsible for the oxidative metabolism of voxelotor.
Created by admin on Wed Aug 04 21:57:02 EDT 2021 , Edited by admin on Wed Aug 04 21:57:02 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
IC50
Created by admin on Wed Aug 04 21:57:07 EDT 2021 , Edited by admin on Wed Aug 04 21:57:07 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:05 EDT 2021 , Edited by admin on Wed Aug 04 21:57:05 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
IC50
Created by admin on Wed Aug 04 21:57:08 EDT 2021 , Edited by admin on Wed Aug 04 21:57:08 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:57:03 EDT 2021 , Edited by admin on Wed Aug 04 21:57:03 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:02 EDT 2021 , Edited by admin on Wed Aug 04 21:57:02 EDT 2021
INDUCER -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:08 EDT 2021 , Edited by admin on Wed Aug 04 21:57:08 EDT 2021
INDUCER -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:07 EDT 2021 , Edited by admin on Wed Aug 04 21:57:07 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:04 EDT 2021 , Edited by admin on Wed Aug 04 21:57:04 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:10 EDT 2021 , Edited by admin on Wed Aug 04 21:57:10 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:06 EDT 2021 , Edited by admin on Wed Aug 04 21:57:06 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:05 EDT 2021 , Edited by admin on Wed Aug 04 21:57:05 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:07 EDT 2021 , Edited by admin on Wed Aug 04 21:57:07 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:57:07 EDT 2021 , Edited by admin on Wed Aug 04 21:57:07 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
MODERATE
Created by admin on Wed Aug 04 21:57:09 EDT 2021 , Edited by admin on Wed Aug 04 21:57:09 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:07 EDT 2021 , Edited by admin on Wed Aug 04 21:57:07 EDT 2021
INDUCER -> METABOLIC ENZYME
Mediator Substance Details
none
IC50
Created by admin on Wed Aug 04 21:57:08 EDT 2021 , Edited by admin on Wed Aug 04 21:57:08 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:02 EDT 2021 , Edited by admin on Wed Aug 04 21:57:02 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:10 EDT 2021 , Edited by admin on Wed Aug 04 21:57:10 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 21:57:15 EDT 2021 , Edited by admin on Wed Aug 04 21:57:15 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:05 EDT 2021 , Edited by admin on Wed Aug 04 21:57:05 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
Screening of potential CYP2B6 inhibitions illustrates that CYP2B6 activity was extensively inhibited by all tested organophosphate pesticides. Inhibition percentages were 100% with chlorpyrifos.
Created by admin on Wed Aug 04 21:57:02 EDT 2021 , Edited by admin on Wed Aug 04 21:57:02 EDT 2021
INDUCER -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 21:57:07 EDT 2021 , Edited by admin on Wed Aug 04 21:57:07 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MAJOR
Created by admin on Wed Aug 04 21:57:03 EDT 2021 , Edited by admin on Wed Aug 04 21:57:03 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:10 EDT 2021 , Edited by admin on Wed Aug 04 21:57:10 EDT 2021
INDUCER -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:05 EDT 2021 , Edited by admin on Wed Aug 04 21:57:05 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:04 EDT 2021 , Edited by admin on Wed Aug 04 21:57:04 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
WEAK INHIBITOR
Created by admin on Wed Aug 04 21:57:09 EDT 2021 , Edited by admin on Wed Aug 04 21:57:09 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:08 EDT 2021 , Edited by admin on Wed Aug 04 21:57:08 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
Mediator Substance Details
none
MINOR
Created by admin on Wed Aug 04 21:57:09 EDT 2021 , Edited by admin on Wed Aug 04 21:57:09 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:09 EDT 2021 , Edited by admin on Wed Aug 04 21:57:09 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:07 EDT 2021 , Edited by admin on Wed Aug 04 21:57:07 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
Screening of potential CYP2B6 inhibitions illustrates that CYP2B6 activity was extensively inhibited by all tested organophosphate pesticides. Inhibition percentages were 100% with fenitrothion.
Created by admin on Wed Aug 04 21:57:02 EDT 2021 , Edited by admin on Wed Aug 04 21:57:02 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
IC50
Created by admin on Wed Aug 04 21:57:08 EDT 2021 , Edited by admin on Wed Aug 04 21:57:08 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
Mediator Substance Details
none
Ki
Created by admin on Wed Aug 04 21:57:11 EDT 2021 , Edited by admin on Wed Aug 04 21:57:11 EDT 2021
SUBSTRATE -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 21:57:03 EDT 2021 , Edited by admin on Wed Aug 04 21:57:03 EDT 2021
INHIBITOR -> METABOLIC ENZYME
Mediator Substance Details
none
IC50
Created by admin on Wed Aug 04 21:57:09 EDT 2021 , Edited by admin on Wed Aug 04 21:57:09 EDT 2021
Structural Modifications
Modification Type Location Site Location Type Residue Modified Extent Modification Name Modification ID Access
Heme binding [1_436] CYS HEME-CYSTEINE (OXIDIZED) G0HAF1JK3T
Amino Acid Substitution [1_128] SER DEXFOSFOSERINE VI4F0K069V
Name Property Type Amount Referenced Substance Defining Parameters Access References
Molecular Formula CHEMICAL
0
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
0
Created Wed Aug 04 21:56:50 EDT 2021
Created By admin
Last Edited Wed Aug 04 21:56:50 EDT 2021
Last Edited By admin
Index Source Text / Citation Source Type Tags Date Accessed File Access
1 Usmani, Khawja A., et al. "In vitro human metabolism and interactions of repellent N, N-diethyl-m-toluamide." Drug metabolism and disposition 30.3 (2002): 289-294. JA PUBLIC_DOMAIN_RELEASE
2 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
3 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/200796Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
4 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203505Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
5 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212801s000lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
6 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-565_Elestat_BioPharmr.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
7 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200603Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
8 Further Characterization of the Metabolism of Desloratadine and Its Cytochrome P450 and UDP-glucuronosyltransferase Inhibition Potential: Identification of Desloratadine as a Relatively Selective UGT2B10 Inhibitor Faraz Kazmi, Phyllis Yerino, Joanna E. Barbara and Andrew Parkinson Drug Metabolism and Disposition September 2015, 43 (9) 1294-1302; DOI: https://doi.org/10.1124/dmd.115.065011 JA PUBLIC_DOMAIN_RELEASE
9 R Meyer, Markus, and Hans H Maurer. "Metabolism of designer drugs of abuse: an updated review." Current drug metabolism 11.5 (2010): 468-482. JA PUBLIC_DOMAIN_RELEASE
10 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/213137Orig1s000Multidiscipline.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
11 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210496Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
12 Sridar, Chitra, Cesar Kenaan, and Paul F. Hollenberg. "Inhibition of bupropion metabolism by selegiline: mechanism-based inactivation of human CYP2B6 and characterization of glutathione and peptide adducts." Drug Metabolism and Disposition 40.12 (2012): 2256-2266. JA PUBLIC_DOMAIN_RELEASE
13 FDA_SRS SRS NOMEN PUBLIC_DOMAIN_RELEASE AUTO_SELECTED
14 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW
15 http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207103Orig1s000PharmR.pdf NDA PUBLIC REVIEW NOMEN
16 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
17 Franklin, Michael R., and Laura B. Hathaway. "2-Diethylaminoethyl-2, 2-diphenylvalerate-HCl (SKF525A) revisited: comparative cytochrome P450 inhibition in human liver microsomes by SKF525A, its metabolites, and SKF-acid and SKF-alcohol." Drug metabolism and disposition 36.12 (2008): 2539-2546. JA PUBLIC_DOMAIN_RELEASE
18 Ramírez, Jacqueline, et al. "CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes." Drug metabolism and disposition 32.9 (2004): 930-936. JA PUBLIC_DOMAIN_RELEASE
19 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/213217Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
20 Generated from relationship on:'SONIDEGIB' SYSTEM
21 Abass, Khaled, Miia Turpeinen, and Olavi Pelkonen. "An evaluation of the cytochrome P450 inhibition potential of selected pesticides in human hepatic microsomes." Journal of Environmental Science and Health, Part B 44.6 (2009): 553-563. JA PUBLIC_DOMAIN_RELEASE
22 https://en.wikipedia.org/wiki/Selective_serotonin_reuptake_inhibitor WIKI NOMEN PUBLIC_DOMAIN_RELEASE
23 Ellison, Corie A., et al. "Human hepatic cytochrome P450-specific metabolism of the organophosphorus pesticides methyl parathion and diazinon." Drug Metabolism and Disposition 40.1 (2012): 1-5. JA PUBLIC_DOMAIN_RELEASE
24 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208434Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
25 http://www.uniprot.org/uniprot/P20813 SRS NOMEN
26 Abass, Khaled, Miia Turpeinen, and Olavi Pelkonen. "An evaluation of the cytochrome P450 inhibition potential of selected pesticides in human hepatic microsomes." Journal of Environmental Science and Health, Part B 44.6 (2009): 553-563. JA PUBLIC_DOMAIN_RELEASE
27 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210910s000lbl.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
28 SRS import [0UY97CSG1T] SRS NOMEN Fri Apr 28 15:19:07 EDT 2017
29 Casabar, Richard CT, et al. "Metabolism of endosulfan-? by human liver microsomes and its utility as a simultaneous in vitro probe for CYP2B6 and CYP3A4." Drug metabolism and disposition 34.10 (2006): 1779-1785. USPNF PUBLIC_DOMAIN_RELEASE
30 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022529Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
31 Liu, Hong, et al. "Metabolism and disposition of a novel selective ?7 neuronal acetylcholine receptor agonist ABT-126 in humans: characterization of the major roles for flavin-containing monooxygenases and UDP-glucuronosyl transferase 1A4 and 2B10 in catalysis." Drug Metabolism and Disposition 46.4 (2018): 429-439. JA PUBLIC_DOMAIN_RELEASE
32 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207500Orig1207501Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW
33 R Meyer, Markus, and Hans H Maurer. "Metabolism of designer drugs of abuse: an updated review." Current drug metabolism 11.5 (2010): 468-482. JA PUBLIC_DOMAIN_RELEASE
34 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
35 Yu, Jian, Dean G. Brown, and Doug Burdette. "In vitro metabolism studies of nomifensine monooxygenation pathways: metabolite identification, reaction phenotyping, and bioactivation mechanism." Drug metabolism and disposition 38.10 (2010): 1767-1778. JA PUBLIC_DOMAIN_RELEASE
36 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
37 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212839Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
38 Gorman, Gregory S., et al. "In vitro metabolic characterization, phenotyping, and kinetic studies of 9cUAB30, a retinoid X receptor-specific retinoid." Drug metabolism and disposition 35.7 (2007): 1157-1164. JA PUBLIC_DOMAIN_RELEASE
39 dump-public-2021-07-22_UPDATED.gsrs BATCH_IMPORT Wed Aug 04 21:56:04 EDT 2021
40 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214621s000lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
41 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206966lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
42 Subrahmanyam, Vangala, et al. "Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes." Drug Metabolism and Disposition 29.8 (2001): 1146-1155. JA PUBLIC_DOMAIN_RELEASE
43 SRS CODE IMPORT SRS NOMEN Fri Apr 28 15:19:07 EDT 2017
44 R Meyer, Markus, and Hans H Maurer. "Metabolism of designer drugs of abuse: an updated review." Current drug metabolism 11.5 (2010): 468-482. JA PUBLIC_DOMAIN_RELEASE
45 Generated from relationship on:'OXYMETAZOLINE' SYSTEM
46 Pedersen, Anders Just, Trine Hedebrink Petersen, and Kristian Linnet. "In vitro metabolism and pharmacokinetic studies on methylone." Drug Metabolism and Disposition 41.6 (2013): 1247-1255. JA PUBLIC_DOMAIN_RELEASE
47 Kalgutkar, Amit S., and Hang T. Nguyen. "Identification of an N-methyl-4-phenylpyridinium-like metabolite of the antidiarrheal agent loperamide in human liver microsomes: underlying reason (s) for the lack of neurotoxicity despite the bioactivation event." Drug metabolism and disposition 32.9 (2004): 943-952. JA PUBLIC_DOMAIN_RELEASE
48 Foxenberg, Robert J., et al. "Human hepatic cytochrome p450-specific metabolism of parathion and chlorpyrifos." Drug metabolism and disposition 35.2 (2007): 189-193. JA PUBLIC_DOMAIN_RELEASE
49 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
50 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203858Orig1s000ClinpharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
51 Wu, Jianmei, et al. "In vitro metabolism and drug-drug interaction potential of UTL-5g, a novel chemo-and radioprotective agent." Drug Metabolism and Disposition 42.12 (2014): 2058-2067. JA PUBLIC_DOMAIN_RELEASE
52 R Meyer, Markus, and Hans H Maurer. "Metabolism of designer drugs of abuse: an updated review." Current drug metabolism 11.5 (2010): 468-482. JA PUBLIC_DOMAIN_RELEASE
53 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022526Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
54 https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021336s005s010,021708s000lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
55 Franklin, Michael R., and Laura B. Hathaway. "2-Diethylaminoethyl-2, 2-diphenylvalerate-HCl (SKF525A) revisited: comparative cytochrome P450 inhibition in human liver microsomes by SKF525A, its metabolites, and SKF-acid and SKF-alcohol." Drug metabolism and disposition 36.12 (2008): 2539-2546. JA PUBLIC_DOMAIN_RELEASE
56 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209195Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
57 Franklin, Michael R., and Laura B. Hathaway. "2-Diethylaminoethyl-2, 2-diphenylvalerate-HCl (SKF525A) revisited: comparative cytochrome P450 inhibition in human liver microsomes by SKF525A, its metabolites, and SKF-acid and SKF-alcohol." Drug metabolism and disposition 36.12 (2008): 2539-2546. JA PUBLIC_DOMAIN_RELEASE
58 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209939Orig1s000,209940Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
59 Generated from relationship on:'PALBOCICLIB' SYSTEM
60 The Role of Human Hepatic Cytochrome P450 Isozymes in the Metabolism of Racemic 3,4-Methylenedioxy-Methamphetamine and Its Enantiomers Markus R. Meyer, Frank T. Peters and Hans H. Maurer Drug Metabolism and Disposition November 2008, 36 (11) 2345-2354; DOI: https://doi.org/10.1124/dmd.108.021543 JA PUBLIC_DOMAIN_RELEASE
61 Nucleic Acids Research, 2010, Vol. 38, Database issue D237–D243 doi:10.1093/nar/gkp970 JA
62 DRUG METABOLISM HANDBOOK, ED. A.F. NASSER, 2009, PG:371 BOOK NOMEN
63 STN SRS NOMEN
64 Granvil, Camille P., et al. "Role of CYP2B6 and CYP3A4 in the In VitroN-Dechloroethylation of (R)-and (S)-Ifosfamide in Human Liver Microsomes." Drug metabolism and disposition 27.4 (1999): 533-541. JA PUBLIC_DOMAIN_RELEASE
65 Subrahmanyam, Vangala, et al. "Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes." Drug Metabolism and Disposition 29.8 (2001): 1146-1155. JA PUBLIC_DOMAIN_RELEASE
66 Foxenberg, Robert J., et al. "Human hepatic cytochrome p450-specific metabolism of parathion and chlorpyrifos." Drug metabolism and disposition 35.2 (2007): 189-193. JA PUBLIC_DOMAIN_RELEASE
67 http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW NOMEN
68 The Role of Human Hepatic Cytochrome P450 Isozymes in the Metabolism of Racemic 3,4-Methylenedioxyethylamphetamine and Its Single Enantiomers Markus R. Meyer, Frank T. Peters and Hans H. Maurer Drug Metabolism and Disposition June 2009, 37 (6) 1152-1156; DOI: https://doi.org/10.1124/dmd.108.026203 JA PUBLIC_DOMAIN_RELEASE
69 McClue, Steven J., and Iain Stuart. "Metabolism of the trisubstituted purine cyclin-dependent kinase inhibitor seliciclib (R-roscovitine) in vitro and in vivo." Drug metabolism and disposition 36.3 (2008): 561-570. JA PUBLIC_DOMAIN_RELEASE
70 Ellison, Corie A., et al. "Human hepatic cytochrome P450-specific metabolism of the organophosphorus pesticides methyl parathion and diazinon." Drug Metabolism and Disposition 40.1 (2012): 1-5. JA PUBLIC_DOMAIN_RELEASE
71 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210496Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
72 http://dmd.aspetjournals.org/content/39/4/693 WEBSITE NOMEN
73 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
74 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203415Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
75 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211810Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
76 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212839Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
77 Talakad, Jyothi C., et al. "Comparison of in vitro metabolism of ticlopidine by human cytochrome P450 2B6 and rabbit cytochrome P450 2B4." Drug metabolism and disposition 39.3 (2011): 539-550. JA PUBLIC_DOMAIN_RELEASE
78 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212839Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
79 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202992Orig1s000ClinpharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
80 Davies, Benjamin J., et al. "CYP2B6, CYP2D6, and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes." Drug metabolism and disposition 35.1 (2007): 128-138. JA PUBLIC_DOMAIN_RELEASE
81 The Role of Human Hepatic Cytochrome P450 Isozymes in the Metabolism of Racemic 3,4-Methylenedioxyethylamphetamine and Its Single Enantiomers Markus R. Meyer, Frank T. Peters and Hans H. Maurer Drug Metabolism and Disposition June 2009, 37 (6) 1152-1156; DOI: https://doi.org/10.1124/dmd.108.026203 JA PUBLIC_DOMAIN_RELEASE
82 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210910s000lbl.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
83 R Meyer, Markus, and Hans H Maurer. "Metabolism of designer drugs of abuse: an updated review." Current drug metabolism 11.5 (2010): 468-482. JA PUBLIC_DOMAIN_RELEASE
84 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209606Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
85 STN STN (SCIFINDER)
86 Chen, Hao, et al. "Metabolism of (S)-5, 6-difluoro-4-cyclopropylethynyl-4-trifluoromethyl-3, 4-dihydro-2 (1H)-quinazolinone, a non-nucleoside reverse transcriptase inhibitor, in human liver microsomes. Metabolic activation and enzyme kinetics." Drug metabolism and disposition 31.1 (2003): 122-132. JA PUBLIC_DOMAIN_RELEASE
87 Abass, Khaled, Miia Turpeinen, and Olavi Pelkonen. "An evaluation of the cytochrome P450 inhibition potential of selected pesticides in human hepatic microsomes." Journal of Environmental Science and Health, Part B 44.6 (2009): 553-563. JA PUBLIC_DOMAIN_RELEASE
88 Kumar, Gondi N., et al. "Identification of cytochromes P450 involved in the human liver microsomal metabolism of the thromboxane A2 inhibitor seratrodast (ABT-001)." Drug metabolism and disposition 25.1 (1997): 110-115. JA PUBLIC_DOMAIN_RELEASE
89 https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/040745Orig1s003lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
90 Dicke, Kari E., Sara M. Skrlin, and Sharon E. Murphy. "Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6." Drug metabolism and disposition 33.12 (2005): 1760-176 JA PUBLIC_DOMAIN_RELEASE
91 Wu, Jianmei, et al. "In vitro metabolism and drug-drug interaction potential of UTL-5g, a novel chemo-and radioprotective agent." Drug Metabolism and Disposition 42.12 (2014): 2058-2067. JA PUBLIC_DOMAIN_RELEASE
92 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213433Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
93 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211996Orig1s000,%20212161Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
94 Abass, Khaled, Miia Turpeinen, and Olavi Pelkonen. "An evaluation of the cytochrome P450 inhibition potential of selected pesticides in human hepatic microsomes." Journal of Environmental Science and Health, Part B 44.6 (2009): 553-563. JA PUBLIC_DOMAIN_RELEASE
95 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210923Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
96 Abass, Khaled, Miia Turpeinen, and Olavi Pelkonen. "An evaluation of the cytochrome P450 inhibition potential of selected pesticides in human hepatic microsomes." Journal of Environmental Science and Health, Part B 44.6 (2009): 553-563. JA PUBLIC_DOMAIN_RELEASE
97 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
98 Grace, James M., et al. "Metabolism of ?-arteether to dihydroqinghaosu by human liver microsomes and recombinant cytochrome P450." Drug Metabolism and Disposition 26.4 (1998): 313-317. JA PUBLIC_DOMAIN_RELEASE
99 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
100 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211810Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
101 Kamdem, Landry K., David A. Flockhart, and Zeruesenay Desta. "In vitro cytochrome P450-mediated metabolism of exemestane." Drug Metabolism and Disposition 39.1 (2011): 98-105. JA PUBLIC_DOMAIN_RELEASE
102 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210450Orig1s000MultiD.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
103 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE